Extracellular Vesicles as Modulators of Cancer Initiation, Progression and Therapy Resistance—Series II

Dear Colleagues,

Following the successful publication of the first Special Issue of “Extracellular Vesicles as Modulators of Cancer Initiation, Progression and Therapy Resistance”, we are very pleased to launched the new edition, which is dedicated to highlighting the recent developments in this field.

Extracellular vesicles (EVs) are 50–1000 nm sized, membrane-bound particles released by both eukaryotic and prokaryotic cells and involved in cell-to-cell communication. They can be found in various body fluids, such as blood, urine and saliva, and transfer proteins, RNAs, miRNAs and lncRNAs from the originating cells to both neighboring and distant cells.

It is now widely accepted that EVs play a key role in different tumorigenic processes, including cancer proliferation, migration and angiogenesis, as well as tumor drug resistance. Moreover, they are implicated in the interactions between malignant and non-malignant cells in the tumor microenvironment, such as stromal and immune cells. Due to their ubiquitous presence in body fluids and their characteristic of often reflecting the molecular signature of the donor cell, they have recently emerged as promising biomarkers for cancer diagnosis and prognosis. Exciting therapeutic strategies aimed at exploiting EVs as biocompatible drug delivery platforms are also being explored.

This Special Issue focuses on the role of EVs in cancer development, metastasis and therapy resistance. Original papers and review articles on the following topics are welcome: (I) mechanisms of EVs’ release and uptake in cancer; (II) EV-mediated cross-talk between malignant and non-malignant cells in the tumor microenvironment; (III) EVs’ role in the emergence of cancer drug resistance; (IV) EVs as a source of biomarkers for cancer diagnosis and prognosis; (V) EVs as drug delivery vehicles for cancer treatment.

Dr. Fabrizio Fontana
Dr. Priya Samuel
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• extracellular vesicles
• exosomes
• microvesicles
• tumor microenvironment
• cancer drug resistance
• cancer diagnosis
• cancer prognosis
• biomarkers
• liquid biopsies
• cancer therapy

• Extracellular Vesicles as Modulators of Cancer Initiation, Progression and Therapy Resistance in Cells (14 articles)